Capricor Therapeutics (CAPR) Stock Price, News & Analysis

Company Overview

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury. Capricor has completed a Phase II trial in DMD that demonstrated potential functional benefits in ambulatory and non-ambulatory patients, and it has initiated follow-on studies to further characterize safety and efficacy. In addition, Capricor’s CAP-2003 program harnesses exosomes derived from CDCs to deliver bioactive molecules that may promote tissue repair, representing a next-generation approach to regenerative medicine.

Capricor serves patients throughout the United States and collaborates with academic and clinical research institutions to accelerate the translation of its therapies. The company’s research and development efforts are supported by strategic partnerships that provide access to specialized manufacturing, preclinical models, and clinical trial networks. Capricor’s leadership team is led by President and CEO Linda L. Marbán, PhD, who co-founded the company and has overseen its growth from an early-stage venture to a publicly traded biotech enterprise.

Key Stats

• Today's Range: $7.11 to $7.64
• 50-Day Range: $5.94 to $9.07
• 52-Week Range: $5.68 to $23.40
• Volume: 941,360 shs
• Average Volume: 1.92 million shs
• Market Capitalization: $329.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.25
• Consensus Rating: Buy

Capricor Therapeutics Stock Analysis - MarketRank™

Capricor Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 668th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Buy

Consensus Rating

Capricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Capricor Therapeutics has a consensus price target of $22.25, representing about 209.3% upside from its current price of $7.19.

Amount of Analyst Coverage

Capricor Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Capricor Therapeutics is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Capricor Therapeutics is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Capricor Therapeutics has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.57% of the outstanding shares of Capricor Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Capricor Therapeutics has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Capricor Therapeutics has recently increased by 5.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Capricor Therapeutics does not currently pay a dividend.

Dividend Growth

Capricor Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

26.57% of the outstanding shares of Capricor Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Capricor Therapeutics has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Capricor Therapeutics has recently increased by 5.74%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.60

News Sentiment

Capricor Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Capricor Therapeutics this week, compared to 16 articles on an average week.

Search Interest

8 people have searched for CAPR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.50% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 21.68% of the stock of Capricor Therapeutics is held by institutions.

CAPR Stock Analysis - Frequently Asked Questions

How have CAPR shares performed this year?

Capricor Therapeutics' stock was trading at $13.80 at the beginning of 2025. Since then, CAPR stock has decreased by 47.9% and is now trading at $7.1940.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced its quarterly earnings results on Monday, August, 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.09. Capricor Therapeutics had a negative trailing twelve-month return on equity of 62.71% and a negative net margin of 181.71%.
Read the conference call transcript.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/30/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CAPR
• CIK: 1133869
• Web: www.capricor.com
• Phone: 310-358-3200
• Fax: 415-875-7075
• Employees: 101
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Capricor Therapeutics: $22.25
• High Price Target: $30.00
• Low Price Target: $12.00
• Potential Upside/Downside: +199.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.47 million
• Net Margins: -181.71%
• Pretax Margin: -522.48%
• Return on Equity: -62.71%
• Return on Assets: -50.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.37
• Quick Ratio: 4.37

Sales & Book Value

• Annual Sales: $22.27 million
• Price / Sales: 15.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.20 per share
• Price / Book: 2.32

Miscellaneous

• Outstanding Shares: 45,720,000
• Free Float: 40,917,000
• Market Cap: $339.24 million
• Optionable: Optionable
• Beta: 0.73